Table 7.

Resolution of evaluable target joints in subjects receiving prophylaxis in B-LONG/B-YOND (subanalysis 3)

Target joints, n	93
Target joints resolved, n (%)	93 (100.0)
Resolved target joints with ≥6 mo follow-up postresolution, n (%)∗	92 (98.9)
Evaluable target joints with recurrence postresolution, n (%)†,‡	9 (9.8)
Evaluable target joints without recurrence in the postresolution period, n (%)†,‡	83 (90.2)
Median (IQR) postresolution follow-up per target joint, mo	47.4 (19.8-60.6)

A target joint was considered resolved if there were ≤2 spontaneous bleeds in a consecutive 12-month period in the target joint. Target joints were considered evaluable if they had ≥12 months consecutive follow-up and there had been no surgery on the target joint within the 12 months since the start of follow-up.

^∗Percentage based on the number of resolved target joints.

^†Percentage is based on the number of resolved target joints with ≥6 months’ follow-up after resolution.

^‡Recurrence is defined as ≥3 spontaneous bleeds in a single joint within any consecutive 6-month period after the target joint resolution.